Elissa Schwartz Net Worth

The estimated Net Worth of Elissa J. Schwartz is at least $2.74 Tysiąc dollars as of 21 January 2022. Ms. Schwartz owns over 1,000 units of Galectin Therapeutics Inc stock worth over $2,740 and over the last 4 years she sold GALT stock worth over $0. In addition, she makes $0 as Independent Director at Galectin Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms. Schwartz GALT stock SEC Form 4 insiders trading

Elissa has made over 1 trades of the Galectin Therapeutics Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently she bought 1,000 units of GALT stock worth $2,000 on 21 January 2022.

The largest trade she's ever made was buying 1,000 units of Galectin Therapeutics Inc stock on 21 January 2022 worth over $2,000. On average, Elissa trades about 200 units every 0 days since 2021. As of 21 January 2022 she still owns at least 1,000 units of Galectin Therapeutics Inc stock.

You can see the complete history of Ms. Schwartz stock trades at the bottom of the page.

Elissa Schwartz biography

Elissa J. Schwartz Ph.D. serves as Independent Director of the Company. She received a PhD in Biomedical Sciences from Mount Sinai–NYU, a BA in Mathematics from UC Berkeley, and interdisciplinary postdoctoral training in Biomathematics and Biostatistics from UCLA. She is also affiliated with the WSU College of Veterinary Medicine in microbiology and pathology, and she is currently on the WSU COVID-19 modeling task force. Dr. Schwartz is the author of over 30 scientific publications on infectious disease, the immune response, and biological modeling. She serves on the Board of Directors for the Society for Mathematical Biology, and she previously served as a consultant for Pharmerit International, LP, a pharmaceutical economics company. Dr. Schwartz has held fellowships with the Mathematical Biosciences Institute (Ohio State University) and the African Institute for Mathematical Sciences (Cape Town, South Africa), and she served on the teaching faculty for courses in British Columbia, India, and Nepal.

How old is Elissa Schwartz?

Elissa Schwartz is 50, she's been the Independent Director of Galectin Therapeutics Inc since 2020. There are 15 older and 2 younger executives at Galectin Therapeutics Inc. The oldest executive at Galectin Therapeutics Inc is Gilbert Omenn, 79, who is the Independent Director.

What's Elissa Schwartz's mailing address?

Elissa's mailing address filed with the SEC is C/O GALECTIN THERAPEUTICS INC., 4960 PEACHTREE INDUSTRIAL BLVD., STE 240, NORCROSS, GA, 30071.

Insiders trading at Galectin Therapeutics Inc

Over the last 14 years, insiders at Galectin Therapeutics Inc have traded over $21,823,082 worth of Galectin Therapeutics Inc stock and bought 5,077,107 units worth $21,362,250 . The most active insiders traders include Richard E Uihlein, James C Czirr oraz Fund, L.P.10 X Capital Mana.... On average, Galectin Therapeutics Inc executives and independent directors trade stock every 27 days with the average trade being worth of $226,012. The most recent stock trade was executed by Richard A. Jr. Zordani on 22 August 2024, trading 3,500 units of GALT stock currently worth $8,050.

What does Galectin Therapeutics Inc do?

galectin therapeutics (nasdaq: galt) is applying its leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. drug candidates based on the company’s unique carbohydrate technology target galectin proteins which are key mediators of biologic and pathologic function. we use naturally occurring carbohydrate polymers with galactose residues to create complex carbohydrates with specific molecular weights. using these unique carbohydrate-based candidate compounds that bind and inhibit galectin proteins, we are pursuing therapies for indications where galectins have a demonstrated role in the pathogenesis of a particular disease. we focus on diseases with serious, life threatening consequences to patients, and those where current treatment options are limited. our strategy is to establish clinical development approaches that add value to the company in the shortest time possible, and to seek partners as the program advances and requires much

Complete history of Ms. Schwartz stock trades at Galectin Therapeutics Inc

Galectin Therapeutics Inc executives and stock owners

Galectin Therapeutics Inc executives and other stock owners filed with the SEC include:

• Harold Shlevin,
  Director
• Jack Callicutt,
  Chief Financial Officer, Secretary
• Dr. Pol F. Boudes M.D., Ph.D.,
  Chief Medical Officer
• Dr. Pol F. Boudes,
  Chief Medical Officer
• Joel Lewis,
  Pres, CEO & Director
• Kevin Freeman,
  Independent Director
• Joel Lewis,
  President, Chief Executive Officer, Director
• Richard Uihlein,
  Independent Chairman of the Board
• Gilbert Amelio,
  Independent Director
• Gilbert Omenn,
  Independent Director
• Kary Eldred,
  Independent Director
• Eliezer Zomer,
  Executive Vice President - Manufacturing and Product Development
• Marc Rubin,
  Independent Director
• James Czirr,
  Director
• Richard Zordani,
  Independent Director
• Elissa Schwartz,
  Independent Director
• Pol Boudes,
  Chief Medical Officer
• J. Rex Horton,
  Executive Director - Regulatory Affairs and Quality Assurance
• Adam Allgood,
  Executive Director of Clinical Development
• Beth Knowles,
  Exec. Assistant & Officer Mang.
• Robert Tritt,
  Gen. Counsel
• Jack W. Callicutt CPA, CPA,
  CFO, Treasurer & Sec.
• Theodore Daniel Zucconi,
  Director
• John F Mauldin,
  Director
• Fund, L.P.10 X Capital Mana...,
  
• Steven Prelack,
  Director
• Arthur Greenberg,
  Director
• Khurram Jamil,
  Chief Medical Officer
• Benjamin Sr Carson,
  
• Stephen Shulman,
  Director
• Fund, L.P.10 X Capital Mana...,
  
• Peter G Traber,
  CEO and President
• Herman Paul Pressler,
  Director
• Thomas Mcgauley,
  Chief Financial Officer
• Rod D Martin,
  Director
• Jerald K Rome,
  Director
• Fund, L.P.Czirr James C10 X...,